|
1
|
Therasse P, Arbuck SG, Eisenhauer EA,
Wanders J, Kaplan RS, Rubinstein L, Verweij J, Van Glabbeke M, van
Oosterom AT, Christian MC and Gwyther SG: New guidelines to
evaluate the response to treatment in solid tumors. European
organization for research and treatment of cancer, national cancer
Institute of the United States, National Cancer Institute of
Canada. J Natl Cancer Inst. 92:205–216. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Eisenhauer EA, Therasse P, Bogaerts J,
Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S,
Mooney M, et al: New response evaluation criteria in solid tumours:
Revised RECIST guideline (version 1.1). Eur J Cancer. 45:228–247.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Suzuki C, Blomqvist L, Sundin A, Jacobsson
H, Byström P, Berglund, Å Nygren P and Glimelius B: The initial
change in tumor size predicts response and survival in patients
with metastatic colorectal cancer treated with combination
chemotherapy. Ann Oncol. 23:948–954. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Litière S, de Vries EG, Seymour L, Sargent
D, Shankar L and Bogaerts J: RECIST Committee: The components of
progression as explanatory variables for overall survival in the
response evaluation criteria in solid tumours 1.1 database. Eur J
Cancer. 50:1847–1853. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Hurwitz H, Fehrenbacher L, Novotny W,
Cartwright T, Hainsworth J, Heim W, Berlin J, Baron A, Griffing S,
Holmgren E, et al: Bevacizumab plus irinotecan, fluorouracil, and
leucovorin for metastatic colorectal cancer. N Engl J Med.
350:2335–2342. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Venook AP, Niedzwiecki D, Lenz HJ,
Innocenti F, Fruth B, Meyerhardt JA, Schrag D, Greene C, O'Neil BH,
Atkins JN, et al: Effect of first-line chemotherapy combined with
cetuximab or bevacizumab on overall survival in patients with KRAS
wild-type advanced or metastatic colorectal cancer: A randomized
clinical trial. JAMA. 317:2392–2401. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Gill S, Berry S, Biagi J, Butts C, Buyse
M, Chen E, Jonker D, Mărginean C, Samson B, Stewart J, et al:
Progression-free survival as a primary endpoint in clinical trials
of metastatic colorectal cancer. Curr Oncol. 18 Suppl 2:S5–S10.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Loupakis F, Cremolini C, Masi G, Lonardi
S, Zagonel V, Salvatore L, Cortesi E, Tomasello G, Ronzoni M, Spadi
R, et al: Initial therapy with FOLFOXIRI and bevacizumab for
metastatic colorectal cancer. N Engl J Med. 371:1609–1618. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Yamada Y, Takahari D, Matsumoto H, Baba H,
Nakamura M, Yoshida K, Yoshida M, Iwamoto S, Shimada K, Komatsu Y,
et al: Leucovorin, fluorouracil, and oxaliplatin plus bevacizumab
versus S-1 and oxaliplatin plus bevacizumab in patients with
metastatic colorectal cancer (SOFT): An open-label,
non-inferiority, randomised phase 3 trial. Lancet Oncol.
14:1278–1286. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Yamazaki K, Nagase M, Tamagawa H, Ueda S,
Tamura T, Murata K, Eguchi Nakajima T, Baba E, Tsuda M, Moriwaki T,
et al: Randomized phase III study of bevacizumab plus FOLFIRI and
bevacizumab plus mFOLFOX6 as first-line treatment for patients with
metastatic colorectal cancer (WJOG4407G). Ann Oncol. 27:1539–1546.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Tang PA, Bentzen SM, Chen EX and Siu LL:
Surrogate end points for median overall survival in metastatic
colorectal cancer: Literature-based analysis from 39 randomized
controlled trials of first-line chemotherapy. J Clin Oncol.
25:4562–4568. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Buyse M, Burzykowski T, Carroll K,
Michiels S, Sargent DJ, Miller LL, Elfring GL, Pignon JP and
Piedbois P: Progression-free survival is a surrogate for survival
in advanced colorectal cancer. J Clin Oncol. 25:5218–5224. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Van Cutsem E, Köhne CH, Hitre E, Zaluski
J, Chang Chien CR, Makhson A, D'Haens G, Pintér T, Lim R, Bodoky G,
et al: Cetuximab and chemotherapy as initial treatment for
metastatic colorectal cancer. N Engl J Med. 360:1408–1417. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Douillard JY, Siena S, Cassidy J,
Tabernero J, Burkes R, Barugel M, Humblet Y, Bodoky G, Cunningham
D, Jassem J, et al: Randomized, phase III trial of panitumumab with
infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4)
versus FOLFOX4 alone as first-line treatment in patients with
previously untreated metastatic colorectal cancer: The PRIME study.
J Clin Oncol. 28:4697–4705. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Cunningham D, Lang I, Marcuello E, Lorusso
V, Ocvirk J, Shin DB, Jonker D, Osborne S, Andre N, Waterkamp D, et
al: Bevacizumab plus capecitabine versus capecitabine alone in
elderly patients with previously untreated metastatic colorectal
cancer (AVEX): An open-label, randomised phase 3 trial. Lancet
Oncol. 14:1077–1085. 2013. View Article : Google Scholar : PubMed/NCBI
|
